ArticleFrontiers in endocrinology2025
Serum Isthmin-1 levels are positively correlated with macrovascular complications in type 2 diabetic patients.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Serum Isthmin-1 in Gestational Diabetes Mellitus: A Case-Control Study Providing Preliminary Evidence of Elevated Levels and Association With Insulin Resistance.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Isthmin-1 (ISM-1), a novel adipokine, has dual effects of increasing fat and glucose uptake while inhibiting hepatic fat synthesis. However, little literature has been found dealing with ISM-1 levels in type 2 diabetes patients with macroangiopathy. The aim of the study was to evaluate possible relationships between ISM-1 peptide levels and macrovascular (MACV) complications in type 2 diabetic subjects. Methods: The study groups consisted of 20 normal controls (NC), 20 T2DM subjects, and 65 MACV subjects. Serum ISM-1 concentrations were determined using immunosorbent assay kits. Linear regression analysis was used to assess the correlation between serum ISM-1 levels and glucose and lipid indicators. Results: The results showed that the serum ISM-1 levels were higher in T2DM subjects than normal controls but lower than MACV subjects (1.20 (0.86, 1.83) vs. 2.07 (1.06, 4.09), P<0.0001). In addition, positive correlations were found between: ISM-1 and systolic blood pressure (SBP) (r = 0.2934; P= 0.0024), ISM-1 and diastolic blood pressure (DBP) (r = 0.2041; P= 0.0368), ISM-1 and triglyceride (TG) (r = 0.3388; P= 0.0004), ISM-1 and FBG (r = 0.2586; P= 0.0077), ISM-1 and HbA1c (r = 0.4002; P< 0.0001), ISM-1 and TyG index (r = 0.3342; P= 0.0005), ISM-1 and HOMA-IR (r = 0.2558; P = 0.0085) in both MACV, T2DM and normal control subjects. Negative correlations were found between ISM-1 and high-density lipoprotein cholesterol (HDL-C) (r = -0.4065; P< 0.0001) and ISM-1 and HOMA-IS (r = -0.2106; P = 0.0319) in both subjects. Conclusions: Our results indicated that MACV individuals have higher serum ISM-1 levels, and ISM-1 was positively correlative to glucolipid metabolism and blood pressure, suggesting ISM-1 may participate in the occurrence and development of MACV mainly by affecting glucose and lipid metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.